RE:RE:Combo tests with anti PD-L1 chekpoint inhibitors Also, no scientific explaination is given that would justify why TH1902 allows these leukocytes to migrate into the mouse tumor."
I am just guessing but as we know Sortilin progressively is over expressed in late stage cancers and it seems it has a contributing function in tumor cells evasions from
the immune system so as TH1902 binds to receptor and internalize into cell the temporary reduction(the receptor goes back to the cell surface once released from TH1902) of the receptor opens a window for immune cells to infiltrate the cancer cells. It could be totally unrelated just hypothetical explanation. But somehow the presence of TH1902 allows the immune cells infiltration into cancerous cells, can't think of anything else...
"Thus, by highlighting the significant relationship between immune cell infiltration and Sort1 expression, the results suggest not only that Sort1 is involved in the HCC tumor microenvironment but also that this process could be important for allowing tumor cells to evade the immune system."
Sortilin 1 Promotes Hepatocellular Carcinoma Cell Proliferation and Migration by Regulating Immune Cell Infiltration - PMC
Mannequin wrote: Does CM @ Thera read your commentary and think "I know" or "hmmm I had not thought of that".
jfm1330 wrote: I finally read this article about pre-clinical work. When it was published, I had other stuff to worry about starting chemo treatment, and I was also fed up with Thera's lack of disclosure about their clinical results, so to read about another pre-clinical study about results on mice was a little too much for me at the time. By the way, I went to see my oncologist today after my Ga68 SPECT scan from Monday, the result was is that my cancer is stable for the last four months. So I will continue on that chemo for at least another four months. My quality of life is degraded, especially for 10-12 days every 28 days, but hey, it's the price to pay to live longer. But I can tell you that to be able to keep a decent quality of life is critical to stay on an anti-cancer treatment. I am still above that line, so I will continue.
So back to this pre-clinical stuff. It's pretty interesting, even though on mice. I was most impressed with the change that allow different types of leukocytes (white blood cells) to penetrate a tumor, even one on mice. As always, the problem is to know how that would translate in real tumors on real human patients, and with other types of cancers. Also, no scientific explaination is given that would justify why TH1902 allows these leukocytes to migrate into the mouse tumor.
Obviously, when you read these results, the first reaction is to want to see them testing it on humans as soon as possible, but they don't identify which anti-PD-L1 checkpoint inhibitors were tested, so it's impossible to identify exactly the company that could be a partner for Thera. A quick search gave me these three monoclonal antibodies as PD-L1 inhibitors: atezolizumab (Tecentriq, Genentech), avelumab (Bavenico, Pfizer) and durvalumab (Imfinzi, MedImmune/Astra Zeneca).